DANBURY, Conn., March 8, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time). The update will include information about the development of new follow-on ultra-rapid-acting insulin formulations including milestones and timelines.
The Roth 23rd Annual OC Growth Stock Conference will be held March 13-16, 2011, at The Ritz Carlton, Laguna Niguel in Dana Point, California.
Interested parties may access the presentation in the investor relations section of Biodel's website at www.biodel.com which will link to a live webcast to be archived for 14 days.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. For further information regarding Biodel, please visit the company's website at www.biodel.com.
CONTACT: Seth Lewis, +1-646-378-2952
SOURCE Biodel Inc.